Table 1 The baseline characteristics of patients with and without significant improvement in LVEF

Age (yrs)

63 ± 10

64 ± 10

60 ± 8

0.183

Female

5

5

0

0.570

GFR ml/min

91 ± 33

88 ± 34

101 ± 27

0.184

BSA (m ² )

2 ± 0.2

2 ± 0.3

2 ± 0.1

0.516

Hypertension

42

32

10

0.562

Diabetes mellitus

7

5

2

0.786

Previous documented MI

42

32

10

0.562

NYHA functional class

2.7 ± 0.8

2.6 ± 0.8

2.7 ± 1.0

0.634

CABG

34

26

8

0.512

ONBEAT

7

6

1

0.518

ONSTOP

27

20

7

0.518

Nr. of distal anastomoses

2.3 ± 1.6

2.2 ± 1.6

2.6 ± 1.6

0.422

LIMA

27

22

5

0.195

PCI

12

10

2

-

Beta-blocker

40

31

9

1.000

ACE inhibitor

33

27

6

0.351

Statin

37

28

9

0.389

Duration between revascularisation and follow-up CMR (weeks)

28 ± 4

28 ± 3

29 ± 8

0.704

LVEF (%)

35 ± 8

36 ± 8

32 ± 7

0.041

LVEF 30% or less

10

7

3

0.474

LV EDVI (ml/m ² )

95 ± 35

90 ± 35

114 ± 30

0.035

LV ESVI (ml/m ² )

62 ± 28

58 ± 28

77 ± 22

0.009

LV SI

0.56 ± 0.1

0.55 ± 0.1

0.6 ± 0.1

0.068

WMSI

1.9 ± 0.4

1.8 ± 0.4

2.2 ± 0.4

0.003

Total LGE score

1.0 ± 0.6

0.9 ± 0.6

1.2 ± 0.7

0.170

LGE mass (g)

31 ± 21

29 ± 21

36 ± 21

0.311